Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: A simple CBC-based scoring system

Cancer

Volumn 106, Issue 3, 2006, Pages 623-630

  Dingli, David ^a   Schwager, Susan M ^a   Mesa, Ruben A ^a   Li, Chin Yang ^a   Tefferi, Ayalew ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Agnogenic myeloid metaplasia; Myelofibrosis; Prognostic models; Survival

Indexed keywords

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD CELL COUNT; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; SCORING SYSTEM;

ADOLESCENT; ADULT; AGE OF ONSET; BLOOD CELL COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOID METAPLASIA; PATIENT SELECTION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 31544454193     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21644     Document Type: Article

References (31)

1. Tefferi A. Myelofibrosis with myeloid metaplasia.[see comment]. N Engl J Med. 2000;342:1255-1265.
2. Barosi G. Myelofibrosis with myeloid metaplasia. Hematol Oncol Clin North Am. 2003;17:1211-1226.
3. Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia; an Olmsted County Study, 1976-1995. Am J Hematol. 1999;61:10-15.
4. Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev. 1997;11:233-242.
5. Anderson JE, Sale G, Appelbaum FR, et al. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol. 1997;98:1010-106.
6. Guardiola P, Esperou H, Cazals-Hatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation. Br J Haematolo. 1997;98:1004-1009.
7. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912-3918.
8. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684-690.
9. Cervantes F, Barosi G, Hernandez-Boluda JC, et al. Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. Eur J Haematol. 2001;66:324-327.
10. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4-9.
11. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.[see comment]. Blood. 1996;88:1013-1018.
12. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635-640.
13. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104:730-737.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Cox D. Regression models with life tables (with discussion). J Royal Stat Soc. 1972;34:187-220.
16. Tefferi A, Mesa RA, Schroeder G, et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113:763-771.
17. Tefferi A DD, Li, C-Y, Dewald GW. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer. 2005;104:1656-1660.
18. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105:973-977.
19. Manoharan A, Hargrave M, Gordon S. Effect of chemotherapy on tear drop poikilocytes and other peripheral blood findings in myelofibrosis. Pathology. 1988;20:7-9.
20. Hasselbalch H. Idiopathic myelofibrosis: a review. Eur J Haematol. 1990;45:65-72.
21. Dingli D, Mesa RA, Tefferi A. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern Med. 2004;43:540-547.
22. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
23. Jones AV, Kreil, S., Zoi, K., Waghorn, K., Curds, C., Zhang, L. et al: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168. Epub 2005 May 26.
24. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
25. Tefferi A. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new. Semin Hematol. 2003;40:18-21.
26. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579-585.
27. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954-2970.
28. Cervantes F, Tassies D, Salgado C, et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematologica. 1991;85:124-127.
29. Varki A, Lottenberg R, Griffith R, et al. The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine. 1983;62:353-371.
30. Thiele J, Kvasnicka HM, Steinberg T, Zankovich R, Fischer R, Diehl V. Survival in primary (idiopathic) osteomyelofibrosis, so called agnogenic myeloid metaplasia. Leuk Lymphoma. 1992;6:389.
31. Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997;98:96-102.